You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH)獲得MPP授權生產口服新冠治療藥物
uSMART盈立智投 03-18 08:41

智通財經APP訊,復星醫藥(600196.SH)發佈公告,近日,MPP(即“藥品專利池組織”)發佈公告及相關媒體報道稱,MPP向包括復星醫藥在內的35家藥企授權生產口服新冠治療藥物奈瑪特韋、奈瑪特韋/利託那韋組合包裝藥物。

MPP授予本公司控股子公司復星醫藥產業使用相關專利和專有技術生產口服新冠治療藥物“奈瑪特韋(Nirmatrelvir)”的仿製藥和許可產品“奈瑪特韋/利託那韋組合”,並在區域內(即印度、巴基斯坦、科特迪瓦等95箇中低收入國家,不包括中國)商業化許可產品及相關權利的非獨家許可。

許可產品是口服小分子新冠治療藥物“奈瑪特韋/利託那韋組合”,用於治療成人伴有進展爲重症高風險因素的輕至中度新型冠狀病毒肺炎(COVID-19)患者。鑑於本次許可旨在幫助95箇中低收入國家可負擔地獲取許可產品,相關定價預計將低於原研產品或在其他中高收入國家的售價。截至本公告日,本次許可項下許可產品的具體成本和定價等暫無法確定。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account